Economic benefits and costs associated with target vaccinations

Journal of Managed Care Pharmacy

Volumn 13, Issue 7 SUPPL., 2007, Pages

  Armstrong, Edward P ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

Cost; Cost effective; Hepatitis; HPV; Pharmacoeconomic; Vaccine

Indexed keywords

CHICKENPOX VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; MEASLES VACCINE; MUMPS VACCINE; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE; RUBELLA VACCINE; VACCINE; WART VIRUS VACCINE; YELLOW FEVER VACCINE;

AGE DISTRIBUTION; CHICKENPOX; CONDYLOMA; CONFERENCE PAPER; CONGENITAL RUBELLA SYNDROME; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIPHTHERIA; DRUG CONJUGATION; HEALTH CARE COST; HEALTH ECONOMICS; HEALTH PROGRAM; HEPATITIS A; HEPATITIS B; HEPATITIS C; HUMAN; INFLUENZA; LIFE EXPECTANCY; LOBAR PNEUMONIA; MEASLES; MUMPS; NEWBORN TETANUS; PERTUSSIS; POLIOMYELITIS; PUBLIC HEALTH; QUALITY OF LIFE; RUBELLA; TETANUS; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; VACCINATION; YELLOW FEVER;

EID: 35349015305     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2007.13.s7-b.12     Document Type: Conference Paper

References (18)

1. Ehreth J. The global value of vaccination. Vaccine. 2003;21:596-600.
2. Gardner P, Pickering LK, Orenstein WA, Gershon AA, Nichol KL. Infectious Diseases Society of America. Guidelines for quality standards for immunization. Clin Infect Dis. 2002;35:503-11.
3. Abramson JS, Pickering LK. US immunization policy. JAMA. 2002;287:505-09.
4. Centers for Disease Control and Prevention. Ten great public health achievements-United States, 1900-1999. MMWR Morb Mortal Wkly Rep. 1999;48:242-64.
5. Centers for Disease Control and Prevention. Notifiable diseases/deaths in selected cities weekly information. MMWR Morb Mortal Wkly Rep. 2005;53:1213-21.
6. Meltzer MI. Introduction to health economics for physicians. Lancet. 2001;358:993-98.
7. Ekwuene DU, Strebel PM, Hadler SC, Meltzer MI, Allen JW, Livengood JR. Economic evaluation of use of diphtheria, tetanus, and acellular pertussis vaccine or diphtheria, tetanus, and whole-cell pertussis vaccine in the United States, 1997. Arch Pediatr Adolesc Med. 2000;154:797-803.
8. Margolis HS, Coleman PJ, Brown RE, Mast EE, Sheingold SH, Arevalo JA. Prevention of hepatitis B virus transmission by immunization. An economic analysis of current recommendations. JAMA. 1995;274:1201-08.
9. Lieu TA, Cochi SL, Black SB, et al. Cost-effectiveness of a routine varicella vaccination program for US children. JAMA. 1994;271:375-81.
10. Lieu TA, Ray GT, Black SB, et al. Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children. JAMA. 2000;283:1460-68.
11. Jacobs RJ, Meyerhoff AS. Comparative cost effectiveness of varicella, hepatitis A, and pneumococcal conjugate vaccines. Prev Med. 2001;33:639-45.
12. Miller MA, Sutter RW, Strebel PM, Hadler SC. Cost-effectiveness of incorporating inactivated poliovirus vaccine into the routine childhood immunization schedule. JAMA. 1996;276:967-71.
13. Jakiche R, Borrego ME, Raisch DW, Gupchup GV, Pai MA, Jakiche A. The cost-effectiveness of two strategies for vaccinating US veterans with hepatitis C virus infection against hepatitis A and hepatitis B viruses. Am J Med Sci. 2007;333:26-34.
14. Scott II RD, Meltzer MI, Erickson LJ, De Wals P, Rosenstein NE. Vaccinating first-year college students living in dormitories for meningococcal disease. An economic analysis. Am J Prev Med. 2002;23:98-105.
15. Dasbach EJ, Elbasha EH, Insinga RP. Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease. Epidemiol Rev. 2006;28:88-100.
16. Sanders GD, Taira AV. Cost effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis. 2003;9:37-48.
17. Taira AV, Neukermans CP, Sanders GD. Evaluating human papillomavirus vaccination programs. Emerg Infect Dis. 2004;10:1915-23.
18. Abramon JS, Pickering LK. US immunization policy. JAMA. 2002;287:505-09.